Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

“The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase ...

GSK's six-monthly IL-5 inhibitor depemokimab clears two phase 3 trials in chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication.

Meanwhile, the ANCHOR-1 and ANCHOR-2 trials in CRSwNP showed that the drug was able to nasal polyp size, as well as nasal obstruction compared to placebo over a year.

AVT23 is a proposed biosimilar to Xolair® (omalizumab). Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E (IgE). Xolair®, which contains omalizumab, is indicated for ...

Omalizumab, a humanized monoclonal antibody that targets free IgE, is indicated for the treatment of severe allergic asthma (>6 years old), chronic rhinosinusitis with nasal polyps (CRSwNP) (>18 years ...

See the latest Regeneron Pharmaceuticals Inc stock price (REGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Read about Regeneron Pharmaceuticals Inc (REGN:XNAS) stock and today's latest news and financial updates.

Background: Many topical products are used in the genital region. Allergic contact dermatitis (ACD) may develop from product use or due to treatment of an underlying dermatosis. Objectives: Our goal ...

Long-term air pollution exposure in adults, even at low levels, is linked to increased risk for pneumonia and other acute lower respiratory infections (ALRIs) requiring hospital care, according to ...